Performance of the BD MAX MDR-TB assay in a clinical setting and its impact on the clinical course of patients with pulmonary tuberculosis: a retrospective before-after study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Missing isoniazid (INH) resistance during tuberculosis (TB) diagnosis can worsen the outcomes of INH-resistant TB. The BD MAX MDR-TB assay (BD MAX) facilitates the rapid detection of TB and INH and rifampin (RIF) resistance; however, data related to its performance in clinical setting remain limited. Moreover, its effect on treatment outcomes has not yet been studied. Methods: We compared the performance of BD MAX for the detection of INH/RIF resistances to that of the line probe assay (LPA) in patients with pulmonary TB (PTB), using the results of a phenotypic drug sensitivity test as a reference standard. The treatment outcomes of patients who used BD MAX were compared with those of patients who did not. Results: Of the 83 patients included in the study, the BD MAX was used for an initial PTB diagnosis in 39 patients. The sensitivity of BD MAX for detecting PTB was 79.5%. The sensitivity and specificity of BD MAX for INH resistance were both 100%, whereas these were 50.0% and 95.8%, respectively, for RIF resistance. The sensitivity and specificity of BD MAX were comparable to those of LPA. The BD MAX group had a shorter time interval from specimen request to the initiation of anti-TB drugs (2.0 days vs. 5.5 days, p=0.001). Conclusion: BD MAX showed comparable performance to conventional tests for detecting PTB and INH/RIF resistances. The implementation of BD MAX as a diagnostic tool for PTB resulted in a shorter turnaround time for the initiation of PTB treatment.
Abstract
Background: Missing isoniazid (INH) resistance during tuberculosis (TB) diagnosis can worsen the outcomes of INH-resistant TB. The BD MAX MDR-TB assay (BD MAX) facilitates the rapid detection of TB and INH and rifampin (RIF) resistance; however, data related to its performance in clinical setting remain limited. Moreover, its effect on treatment outcomes has not yet been studied. Methods: We compared the performance of BD MAX for the detection of INH/RIF resistances to that of the line probe assay (LPA) in patients with pulmonary TB (PTB), using the results of a phenotypic drug sensitivity test as a reference standard. The treatment outcomes of patients who used BD MAX were compared with those of patients who did not. Results: Of the 83 patients included in the study, the BD MAX was used for an initial PTB diagnosis in 39 patients. The sensitivity of BD MAX for detecting PTB was 79.5%. The sensitivity and specificity of BD MAX for INH resistance were both 100%, whereas these were 50.0% and 95.8%, respectively, for RIF resistance. The sensitivity and specificity of BD MAX were comparable to those of LPA. The BD MAX group had a shorter time interval from specimen request to the initiation of anti-TB drugs (2.0 days vs. 5.5 days, p=0.001). Conclusion: BD MAX showed comparable performance to conventional tests for detecting PTB and INH/RIF resistances. The implementation of BD MAX as a diagnostic tool for PTB resulted in a shorter turnaround time for the initiation of PTB treatment.
참고문헌 (31)
- "Global tuberculosis report 2023" (2023)[URL]
- "Annual report on the notified tuberculosis in Korea, 2022" (2023)[URL]
- Jhun BW, "Treatment of isoniazid-resistant pulmonary tuberculosis", Tuberc Respir Dis(Seoul), 83, pp.20~30 (2020)
- Jhun BW, "Diagnosis of pulmonary tuberculosis", J Korean Med Assoc, 62, pp.18~24 (2019)
- Kim YW, "Evaluation of Xpert(®)MTB", RIF assay : diagnosis and treatment outcomes in rifampicin-resistant tuberculosis, 2015, pp.19, 1216~1221
- "WHO consolidated guidelines on tuberculosis: module 3: diagnosis–rapid diagnostics for tuberculosis detection" (2020)[URL]
- Miotto P, "A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis", Eur Respir J, 50, pp.1701354~ (2017)
- Yadav RN, "Comparative performance of line probe assay(version 2)and Xpert MTB", RIF assay for early diagnosis of rifampicin-resistant pulmonary tuberculosis, 2021, pp.84, 237~244
- Nathavitharana RR, "Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis : a systematic review and meta-analysis", Eur Respir J, 49, pp.1601075~ (2017)
- "The use of molecular line probe assay for the detection of resistance to isoniazid and rifampicin: policy update" (2016)[URL]
- "WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment" (2020)[URL]
- Menzies D, "Standardized treatment of active tuberculosis in patients with previous treatment and", or with mono-resistance to isoniazid : a systematic review and meta-analysis, 2009, pp.6, e1000150~
- Gegia M, "Treatment of isoniazid-resistant tuberculosis with first-line drugs : a systematic review and meta-analysis", Lancet Infect Dis, 17, pp.223~234 (2017)
- Romanowski K, "The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis : a modelling study", PLoS One, 14, pp.e0211355~ (2019)
- Shah M, "Multicenter study of the accuracy of the BD MAX multidrug-resistant tuberculosis assay for detection of mycobacterium tuberculosis complex and mutations associated with resistance to rifampin and isoniazid", Clin Infect Dis, 71, pp.1161~1167 (2020)
- Beutler M, "A pre-clinical validation plan to evaluate analytical sensitivities of molecular diagnostics such as BD MAX MDR-TB, Xpert MTB", Rif Ultra and FluoroType MTB, 2020, pp.15, e0227215~
- Ciesielczuk H, "Evaluation of the BD MAX™ MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB", Eur J Clin Microbiol Infect Dis, 39, pp.1321~1327 (2020)
- Hofmann-Thiel S, "Clinical evaluation of BD MAX MDR-TB assay for direct detection of mycobacterium tuberculosis complex and resistance markers", J Mol Diagn, 22, pp.1280~1286 (2020)
- Linh NN, "World Health Organization treatment outcome definitions for tuberculosis : 2021 update", Eur Respir J, 58, pp.2100804~ (2021)
- Ko Y, "Accuracy of Xpert(®)MTB", RIF assay compared with AdvanSure™ TB, Int J Tuberc Lung Dis, pp.2016, 20[DOI]
- Son E, "Head-to-head comparison between Xpert MTB", RIF assay and real-time polymerase chain reaction assay using bronchial washing specimens for tuberculosis diagnosis, 2022, pp.85, 89~95
- Lee HY, "Diagnostic accuracy of Xpert® MTB", RIF on bronchoscopy specimens in patients with suspected pulmonary tuberculosis, 2013, pp.17, 917~921
- Jo YS, "Discordance between MTB", RIF and real-time tuberculosis-specific polymerase chain reaction assay in bronchial washing specimen and its clinical implications, 2016, pp.11, e0164923~
- Kwak SH, "Characteristics and risk factors associated with missed diagnosis in patients with smear-negative pulmonary tuberculosis", Korean J Intern Med, 36(Suppl 1), pp.S151~S159 (2021)
- Kwak N, "Diagnostic accuracy and turnaround time of the Xpert MTB", RIF assay in routine clinical practice, 2013, pp.8, e77456~
- Kim J, "Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis", Int J Infect Dis, 42, pp.64~68 (2016)
- Singh BK, "Diagnostic evaluation of non-interpretable results associated with rpoB gene in genotype MTBDRplus ver 2.0", Tuberc Respir Dis (Seoul), 83, pp.289~294 (2020)
- Rufai SB, "Comparison of Xpert MTB", RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis, 2014, pp.52, 1846~1852
- Hughes D, "Rifampicin resistance: fitness costs and the significance of compensatory evolution", Antibiotics(Basel), 2, pp.206~216 (2013)
- Zetola NM, "Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB", RIF are associated with poor clinical outcomes, 2014, pp.52, 2422~2429
- Georghiou SB, "Guidance for studies evaluating the accuracy of rapid tuberculosis drug-susceptibility tests", J Infect Dis, 220(Suppl 3), pp.S126~S135 (2019)